TheFiscalFinder
Contractors / Emergent Biosolutions Canada Inc

Emergent Biosolutions Canada Inc

FY2026 · year to date · preliminary · data as of 2026-09-12†

† DoD contract data posts to USAspending about 90 days after award.

prime recipient of federal awards · UEI XM23STFMVML6 Source
$118.3M
obligated · FY2026 YTD
1
funding agencies
100%
from Health and Hum…
100%
non-competed
1
industries

Key takeaways

Computed
FY2026 · year to date · preliminary · data as of 2026-09-12
  • Emergent Biosolutions Canada Inc has received $118.3M in federal obligations so far in FY2026.
  • The Department of Health and Human Services accounted for 100% of it.
  • Of its $118.3M in contract obligations, 100% was non-competed, based on FPDS extent-competed codes.
  • Its largest recorded industry was Pharmaceutical Preparation Manufacturing, at $118.3M.

Obligations by year

Computed
$132.9M
FY23
$118.3M
FY26 YTD

Where this money comes from

Source
FUNDING AGENCIES
EMERGENT BIOSOLUTIONS CA
HHS
$0.1B
Emergent Biosolutions Canada Inc
$0.1B
FY2026 obligated
band width = obligations · FY2026 · source: USASpending.gov

Awards

Source

Largest active awards by total value

Awards whose period of performance overlaps FY2026, by the amount obligated on each so far.

AwardIDAgencyObligatedStartEndPlace
Vigiv Buy and Associated Services75A50119C00037Department of Health and Human Services$422.3M2019-05-312027-03-30—
Botulism Antitoxin75A50119C00075Department of Health and Human Services$320.9M2019-09-302027-03-30—

Largest FY2026 awards

Awards that started in FY2026 so far, by the amount obligated on each so far.

No award on record started in FY2026.

What it does (NAICS / PSC)

Pharmaceutical Preparation Manufacturing$118.3M

Where the work lands

No places of performance recorded.

Competition

100%non-competed (often called no-bid), of $118.3M in contract obligations in FY2026Computed

This describes how contracts were awarded, not wrongdoing.

Similar federal contractors

Computed
Mckesson Corporation$12.3B
Merck Sharp & Dohme LLC$2.3B
Pfizer Inc$1.1B
Glaxosmithkline, LLC$1B
Sanofi Vaccines US Inc.$734.3M
Phlow Corp.$105.3M
Exelan Pharmaceuticals Inc$105M
Canadian Commercial Corporation$14.3M

Corporate family

Single registration: no combined family.

Related

🔎
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.